Molecular and clinical aspects of the Neu/ErbB-2 receptor tyrosine kinase

  • Ilana Stancovski
  • Michael Sela
  • Yosef Yarden
Part of the Cancer Treatment and Research book series (CTAR, volume 71)


Tumorigenesis in model experimental systems involves multiple steps that include activation of cell growth and inactivation of inhibitory processes [1,2]. Tumor development in humans is thought to reflect the multiplicity of events in the accumulation of independent mutations that affect clonal growth of the cancerous cell [3]. The identity of the group of genes that confer malignancy in vitro appears to be similar to the set of genes that are mutated in animal and human tumors [4]. All the genes whose products undergo mutational activation (oncogenes) encode key regulatory elements in signal transduction pathways that lead to cell growth [5]. Thus, oncogenic proteins may be growth factors, their membrane receptors, cytoplasmic effector proteins, or nuclear factors that control gene expression. In animal model systems, altered forms of receptors for growth factors can induce tumorigenesis. Examples are the products of the fms and erbB retroviral genes that encode portions of the receptors for colony stimulating factor 1 (CSF-1) [6] and epidermal growth factor (EGF) [7], respectively. However, the possibility that modifications of growth factor receptors may be one of the molecular steps that are crucial for tumor development in humans remains open.


Breast Cancer Epidermal Growth Factor Receptor Bispecific Antibody Chimeric Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Nowell P. 1976. The clonal evolution of tumor cell populations. Science 194: 23–28.PubMedGoogle Scholar
  2. 2.
    Weinberg RA. 1989. Oncogenes, anti-oncogenes and the molecular bases of multistep carcinogenesis. Cancer Res 49: 3713–3721.PubMedGoogle Scholar
  3. 3.
    Fearon EF, Vogelstein B. 1990. A genetic model for colorectal tumorigenesis. Cell 61: 759–767.PubMedGoogle Scholar
  4. 4.
    Bishop JM. 1987. The molecular genetics of cancer. Science 235: 305–311.PubMedGoogle Scholar
  5. 5.
    Bishop JM. 1991. Molecular themes in oncogenesis. Cell 64: 235–248.PubMedGoogle Scholar
  6. 6.
    Scherr CJ, Rettenmier CW, Sacca R, Roussel MF, Look AT, Stanley ER. 1985. The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1. Cell 41: 665–671.Google Scholar
  7. 7.
    Downward J, Yarden Y, Mayes E, Scrace G. Totty N, Stockwell P, Ullrich A, Schlessinger J, Waterfield M. 1984. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307: 521–527.PubMedGoogle Scholar
  8. 8.
    Cross M, Dexter TM. 1991. Growth factors in development, transformation and tumorigenesis. Cell 64: 271–280.PubMedGoogle Scholar
  9. 9.
    Aaronson SA. 1991. Growth factors and cancer. Science 254: 1146–1153.PubMedGoogle Scholar
  10. 10.
    Rifkin DB, Moscatteli D. 1989. Recent developments in the cell biology of basic fibroblast growth factor. J Cell Biol 109: 1–6.PubMedGoogle Scholar
  11. 11.
    Dickson RB. 1990. Stimulatory and inhibitory growth factors and breast cancer. J Steroid Biochem Mol Biol 37: 795–803.PubMedGoogle Scholar
  12. 12.
    Boyle WJ. 1992. Growth factors and tyrosine kinase receptors during development and cancer. Curr Op Oncol 4: 156–162.Google Scholar
  13. 13.
    Miki T, Fleming TP, Bottaro DP, Rubin JS, Ron D, Aaronson SA. 1991. Expression cloning of cDNA of the KGF receptor by creation of a transforming autocrine loop. Science 251: 72–75.PubMedGoogle Scholar
  14. 14.
    Sizeland AM, Burgess AW. 1991. The proliferative and morphologic responses of a colon carcinoma cell line (LIM 1215) require the production of two autocrine factors. Mol Cell Biol 11: 4005–4015.PubMedGoogle Scholar
  15. 15.
    Yarden Y, Ullrich A. 1988. Growth factor receptor tyrosine kinases. Annu Rev Biochem 57: 443–478.PubMedGoogle Scholar
  16. 16.
    Ullrich A, Schlessinger J. 1990. Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203–212.PubMedGoogle Scholar
  17. 17.
    Cantley LC, Auger K, Carpenter C, Duckworth B, Graziani A, Kapeller R, Soltoff S. 1991. Oncogenes and signal transduction. Cell 64: 281–302.PubMedGoogle Scholar
  18. 18.
    Lev S, Givol D, Yarden Y. 1991. A specific combination of substrates is involved in signal transduction by the kit-encoded receptor. EMBO J 10: 647–654.PubMedGoogle Scholar
  19. 19.
    Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA. 1989. Isolation and characterization of Erb-B3, a third member of the Erb-B/epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci USA 86: 9193–9197.PubMedGoogle Scholar
  20. 20.
    Plowman GD, Greene JM, McDonald UL, Neubauer MG, Disteche CM, Todaro GJ, Shoyab M. 1990. The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity. Mol Cell Biol 10: 1969–1981.PubMedGoogle Scholar
  21. 21.
    Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, Weinberg RA. 1984. The neu-oncogene: an erbB related gene encoding a 185,000 Mr tumor antigen. Nature 312: 513–516.PubMedGoogle Scholar
  22. 22.
    Bargmann CI, Hung M-C, Weinberg RA. 1986. Multiple independent activations of the neu oncogene by a point-mutation altering the transmembrane domain of pl85. Cell 45: 649–657.PubMedGoogle Scholar
  23. 23.
    Schubert D, Heinemann S, Carlisle W, Tarkias H, Kimes B, Patrick J, Steinbach JH, Culp W, Brandt BL. 1974. Clonal cell lines from the rat central nervous system. Nature 249: 224–227.PubMedGoogle Scholar
  24. 24.
    Shih C, Padhy LC, Murray M, Weinberg RA. 1981. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 290: 261–264.PubMedGoogle Scholar
  25. 25.
    Padhy LC, Shih C, Cowing D, Finkelstein R, Weinberg RA. 1982. Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell 28: 865–871.PubMedGoogle Scholar
  26. 26.
    Bargmann CI, Weinberg RA. 1988. Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene. Proc Natl Acad Sci USA 85: 5394–5398.PubMedGoogle Scholar
  27. 27.
    Bargmann CI, Weinberg RA. 1988. Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. EMBO J 7: 2043–2052.PubMedGoogle Scholar
  28. 28.
    King CR, Kraus MH, Aaronson SA. 1985. Amplification of a novel c-erbB-related gene in a human mammary carcinoma. Science 229: 974–976.PubMedGoogle Scholar
  29. 29.
    Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Liebermann TA, Schlessinger J, Francke U, Levinson A, Ullrich A. 1985. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132–1139.PubMedGoogle Scholar
  30. 30.
    Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, Toyoshima K. 1986. Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. Nature 319: 230–237.PubMedGoogle Scholar
  31. 31.
    Akiyama T, Matsuda S, Namba Y, Saito T, Toyoshima K, Yamamoto T. 1991. The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxy-terminal domain. Mol Cell Biol 11: 833–842.PubMedGoogle Scholar
  32. 32.
    Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CH, Aaronson SA. 1987. erbB-2 is a potent oncogene when overexpressed in NIH-3T3 cells. Cell 51: 1063–1070.PubMedGoogle Scholar
  33. 33.
    Mikami Y, Davis JG, Dobashi K, Dougall W, Myers JN, Brown VI, Greene MI. 1992. Carboxyl-terminal deletion and point mutations decrease the transforming potential of the activated rat neu oncogene product. Proc Natl Acad Sci USA 89: 7335–7339.PubMedGoogle Scholar
  34. 34.
    Hudziak RM, Schlessinger J, Ullrich A. 1987. Increased expression of the putative growth factor receptor 185HER-2 causes transformation and tumorigensis of NIH-3T3 cells. Proc Natl Acad Sci USA 84: 7159–7163.PubMedGoogle Scholar
  35. 35.
    Di Marco E, Pierce JH, Knicley CL, Di Fiore PP. 1990. Transformation of NIH-3T3 cells by overexpression of the normal coding sequence of the rat neu gene. Mol Cell Biol 10: 3247–3252.PubMedGoogle Scholar
  36. 36.
    Akiyama T, Saito T, Ogawara H, Toyoshima K, Yamamoto T. 1988. Tumor promoter and epidermal growth factor stimulate phosphorylation of the c-erbB-2 gene product in MKN-7 human adenocarcinoma cells. Mol Cell Biol 8: 1019–1026.PubMedGoogle Scholar
  37. 37.
    Epstein RJ, Druker BJ, Roberts TM, Stiles CD. 1990. Modulation of a Mr 175,000 c-neu receptor isoform in G8/DHFR cells by serum starvation. J Biol Chem 265: 10740–10751.Google Scholar
  38. 38.
    Stern DF, Kamps MP, Cao H. 1988. Oncogenic activation of P185neu stimulates tyrosine phosphorylation in vivo. Mol Cell Biol 8: 3969–3973.PubMedGoogle Scholar
  39. 39.
    King CR, Borrello I, Bellot F, Comoglio P, Schlessinger J. 1988. EGF binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SKBR-3. EMBO J 7: 1647–1651.PubMedGoogle Scholar
  40. 40.
    Kokai Y, Myers YN, Wada T, Brown VI, LeVea CM, Davis JG, Dobashi K, Greene MI. 1990. Synergistic interaction of P185Cneu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 58: 287–292.Google Scholar
  41. 41.
    Müller WJ, Sinn E, Pattengale PK, Wallace R, Leder P. 1988. Single step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54: 105–115.PubMedGoogle Scholar
  42. 42.
    Bouchard L, Lamarre L, Tremblay PJ, Jolicoeur P. 1989. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 57: 931–936.PubMedGoogle Scholar
  43. 43.
    Wang B, Kennan WS, Yasukawa-Barnes J, Lindstrom MJ, Gould MN. 1991. Frequent induction of mammary carcinomas following neu oncogene transfer into in situ mammary epithelial cells of susceptible and resistant rat strains. Cancer Res 51: 5649–5654.PubMedGoogle Scholar
  44. 44.
    Suda Y, Aizawa S, Furuta Y, Yagi T, Ikawa Y, Saitoh K, Yamada Y, Toyoshima K, Yamamoto T. 1990. Induction of a variety of tumors by c-erbB2 and clonal nature of lymphomas even with the mutated gene val659-Glu659. EMBO J 9: 181–190.PubMedGoogle Scholar
  45. 45.
    Kokai Y, Cohen JA, Drebin JA, Greene MI. 1987. Stage-and tissue-specific expression of the neu oncogene in rat development. Proc Natl Acad Sci USA 84: 8498–8501.PubMedGoogle Scholar
  46. 46.
    Press MF, Cordon-Cardo C, Slamon DJ. 1990. Expression of the HER-2/neu protooncogene in normal human adult and fetal tissues. Oncogene 5: 953–962.PubMedGoogle Scholar
  47. 47.
    Cohen JA, Weiner DB, More KF, Kokai Y, Williams WV, Maguire HC, LiVolsi VA, Greene MI. 1989. Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (pl85neu) in normal and transformed epithelial tissues. Oncogene 4: 81–88.PubMedGoogle Scholar
  48. 48.
    Stoica G, Koestner A. 1984. Diverse spectrum of tumors in male Spraguc-Dawlcy rats following single high doses of N-ethyl-nitrosourea (ENU). Am J Pathol 116: 319–326.PubMedGoogle Scholar
  49. 49.
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WI. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182.PubMedGoogle Scholar
  50. 50.
    Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuary SG, Udove J, Ullrich A, Press MF. 1989. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244: 707–712.PubMedGoogle Scholar
  51. 51.
    Gullick WJ. 1990. The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast cancer. Int J Cancer Suppl 5: 55–61.PubMedGoogle Scholar
  52. 52.
    Perren TY. 1991. c-erbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer 63: 328–332.PubMedGoogle Scholar
  53. 53.
    Gusterson BA. 1992. Identification and interpretation of epidermal growth factor and c-erbB-2 overexpression. Eur J Cancer 28: 263–267.PubMedGoogle Scholar
  54. 54.
    Berns EMJ, Klign JGM, van Patten WLJ, van Staveren IL, Portengen H, Foekens JA. 1992. c-myc amplification is a better prognostic factor than HER-2/neu amplification in primary breast cancer. Cancer Res 52: 1107–1113.PubMedGoogle Scholar
  55. 55.
    Gusterson BA, Machin LG, Gullick WJ, Gibbs NM, Powles TJ, Elliott C, Ashley S, Monaghan P, Harrison S. 1988. c-erbB-2 expression in benign and malignant breast disease. Br J Cancer 58: 453–457.PubMedGoogle Scholar
  56. 56.
    Fox B, Day CA, Rogers S. 1991. Lack of c-erbB-2 oncoprotein expression in male breast carcinoma. J Clin Pathol 44: 960–961.PubMedGoogle Scholar
  57. 57.
    van de Vijver M, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R. 1988. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319: 1239–1245.PubMedGoogle Scholar
  58. 58.
    Ramachandra S, Machin L, Ashley S, Monaghan P, Gusterson BA. 1990. Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma — a detailed morphological analysis. J Pathol 161: 7–14.PubMedGoogle Scholar
  59. 59.
    Lodato RF, Maguire HC Jr, Greene MI, Weiner DB, LiVolsi VA. 1990. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Mod Pathol 3: 499–454.Google Scholar
  60. 60.
    Anbazhagan R, Gelber RD, Bettelheim R, Goldhirsch A, Gusterson BA. 1991. Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer. Ann Oncol 2: 47–53.PubMedGoogle Scholar
  61. 61.
    Baak JP, Chin D, van Diest PJ, Ortiz R, Matze-Cok P, Bacus SS. 1990. Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy and morphometric and clinical features in paraffin-embedded invasive breast cancer. Lab Invest 64: 215–223.Google Scholar
  62. 62.
    Barnes DM, Lammie GA, Millis RR, Gullick WJ, Allen DS, Altman DG. 1988. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. J Cancer 58: 448–452.Google Scholar
  63. 63.
    Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Sigurdsson H. 1991. ErbB-2 amplification in breast cancer with a high rate of proliferation. Oncogene 6: 137–143.PubMedGoogle Scholar
  64. 64.
    Rio MC, Bellocq JP, Gairard B, Rasmussen UB, Krust A, Koehl C, Calderoli H, Schiff V, Renaud R, Chambon P. 1987. Specific expression of pS2 gene in subclasses of breast cancers in comparison with expression of the oestrogen and progesterone receptors and the oncogene erbB2. Proc Natl Acad Sci USA 84: 9243–9247.PubMedGoogle Scholar
  65. 65.
    Guerin M, Gabillot M, Mathieu M-C, Travagli J-P, Spielman M, Andrieu N, Riou G. 1989. Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer 43: 201–208.PubMedGoogle Scholar
  66. 66.
    May E, Mouriesse H, May-Levin F, Quan JF, May P, Delarue JC. 1990. Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression. Br J Cancer 62: 430–435.PubMedGoogle Scholar
  67. 67.
    Cline MJ, Battifora H, Yokota J. 1987. Proto-oncogene abnormalities in human breast cancer: correlations with anatomic features and clinical course of disease. J Clin Oncol 5: 999–1006.PubMedGoogle Scholar
  68. 68.
    Tavassoli M, Quirke P, Farzaneh F, Lock NJ, Mayne LV, Kirkham N. 1989. c-erbB-2/c-erbB-1 co-amplification indicative of lymph node metastasis and c-myc amplification of high tumor grade, in human breast cancer. Br J Cancer 60: 505–510.PubMedGoogle Scholar
  69. 69.
    Seshadri R, Matthews C, Dobrosic A, Horsfall DJ. 1989. The significance of oncogene amplification in primary breast cancer. Int J Cancer 43: 270–272.PubMedGoogle Scholar
  70. 70.
    Noguchi M, Koyasaki N, Ohta N, Kitagawa H, Earashi M, Thomas M, Miyazaki I, Mizukami Y. 1992. c-erbB-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer. Cancer 69: 2953–2960.PubMedGoogle Scholar
  71. 71.
    Zhou DJ, Ahuga H, Cline MJ. 1989. Proto-oncogene abnormalities in human breast cancer: c-erbB-2 amplification does not correlate with recurrence of disease. Oncogene 4: 105–108.PubMedGoogle Scholar
  72. 72.
    Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fuqua SA, Killander D, McGuire WL. 1990. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50: 4332–4337.PubMedGoogle Scholar
  73. 73.
    Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Yamamoto H, Miyajima N, Toyoshima K, Yamamoto T, Yokota J, Yoshida T, Sakamoto H, Terada M, Sugimura T. 1989. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res 49: 3104–3108.PubMedGoogle Scholar
  74. 74.
    Wright C, Angus B, Nicholson S, Sainsbury JRC, Cairns J, Gullick WJ, Kelly P, Harris AL, Home CHW. 1989. Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer. Cancer Res 49: 2087–2090.PubMedGoogle Scholar
  75. 75.
    Walker RA, Gullick WJ, Varlcy JM. 1989. An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. Br J Cancer 60: 426–429.PubMedGoogle Scholar
  76. 76.
    King CR, Swain SM, Porter L, Steinberg SM, Lippman ME, Gelmann EP. 1989. Heterogeneous expression of c-erbB-2 messenger RNA in human breast cancer. Cancer Res 49: 4185–4191.PubMedGoogle Scholar
  77. 77.
    Adnane J, Gaudray P, Simon M-P, Simony-Lafontaine J, Jeanteur P, Theillet C. 1989. Proto-oncogene amplification and breast tumor phenotype. Oncogene 4: 1389–1395.PubMedGoogle Scholar
  78. 78.
    O’Reilly SM, Barnes DM, Camplejohn RS, Bartkova J, Gregory WM, Richard MA. 1991. The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer 63: 444–446.PubMedGoogle Scholar
  79. 79.
    Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL, Altman DG. 1991. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63: 434–438.PubMedGoogle Scholar
  80. 80.
    Lovekin C, Ellis IO, Locker A, Robertson JFR, Bell J, Nicholson R, Gullick WJ, Elston CW, Blarney RW. 1991. c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 63: 439–443.PubMedGoogle Scholar
  81. 81.
    Winstanley J, Cooke T, Murray GD, Platt-Higgins A, George WD, Holt S, Myskov M, Spedding A, Barraclough BR, Rudland PS. 1991. The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 63: 447–450.PubMedGoogle Scholar
  82. 82.
    Garcia I, Dietrich P-Y, Aapro M, Vauthier G, Vadas L, Engel E. 1989. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras proto-oncogenes and clinical associations in human breast carcinomas. Cancer Res 49: 6675–6679.PubMedGoogle Scholar
  83. 83.
    Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR. 1990. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8: 103–112.PubMedGoogle Scholar
  84. 84.
    Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfield MD, Groner B, Hynes NE. 1988. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 48: 1238–1243.PubMedGoogle Scholar
  85. 85.
    Zeilinger R, Kury F, Czerwenka L, Kubista E, Sliutz G, Knogler W, Huber J, Zeilinski C, Reiner G, Jakesz R, Staffen A, Reiner A, Wrba F, Spona J. 1989. HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene 4: 109–114.Google Scholar
  86. 86.
    Heintz NH, Leslie Ko, Rogers LA, Howard PL. 1990. Amplification of the c-erbB-2 oncogene and prognosis of breast adenocarcinomas. Arch Pathol Lab Med 114: 160–163.PubMedGoogle Scholar
  87. 87.
    Borg A, Linell F, Iduall I, Johnsson S, Sigurdsson H, Ferno M, Killander D. 1989. HER-2/neu amplification and comedo type breast carcinoma. Lancet I: 1268–1269.Google Scholar
  88. 88.
    Ro J, El-Haggar A, Ro JY, Blick M, Frye D, Fraschini G, Fritsche H, Hortobagyi G. 1989. c-erbB-2 amplification in node-negative human breast cancer. Cancer Res 49: 6941–6944.PubMedGoogle Scholar
  89. 89.
    Bacus SS, Bacus JW, Slamon DJ, Press MF. 1990. HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer. Arch Pathol Lab Med 114: 164–169.PubMedGoogle Scholar
  90. 90.
    Ali IU, Campbell G, Lidereau R, Callahan R. 1988. Lack of evidence for the prognostic significance of the c-erbB-2 amplification in human breast carcinoma. Oncogene Res 3: 139–146.PubMedGoogle Scholar
  91. 91.
    Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. 1989. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7: 1120–1128.PubMedGoogle Scholar
  92. 92.
    Dykins R, Corbett IP, Henry JA, Wright C, Yuan J, Hennessy C, Lennard TJ, Angus B, Home CH. 1991. Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: an immunohistochemical study using monoclonal antibody NCL-CB11. J Pathol 163: 105–110.PubMedGoogle Scholar
  93. 93.
    Berchuck A, Kamel A, Whitaker R, Kerns B, Ott G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P, McKenzie S, Yin S, Bast RC Jr. 1990. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50: 4087–4091.PubMedGoogle Scholar
  94. 94.
    Hung MC, Zhang X, Yan DH, Zhang HZ, He GP, Zhang TQ, Shi DR. 1992. Aberrant expression of the c-erbB-2/neu in ovarian cancer. Cancer Lett 61: 95–103.PubMedGoogle Scholar
  95. 95.
    Huettner PC, Carney WP, Naber SP, Delellis RA, Membrino W, Wolfe JH. 1992. Neu oncogene expression in ovarian tumors: a quantitative study. Mod Pathol 5: 250–256.PubMedGoogle Scholar
  96. 96.
    King BL, Carter D, Foellmer HG, Kacinski BM. 1992. Neu proto-oncogene amplification and expression in ovarian adenocarcinoma cell lines. Am J Pathol 140: 23–31.PubMedGoogle Scholar
  97. 97.
    Haldane JS, Hird V, Hughes CM, Gullick WJ. 1990. c-erbB-2 oncogene expression in ovarian cancer. J Pathol 162: 231–237.PubMedGoogle Scholar
  98. 98.
    Kacinski BM, Mayer AG, King BL, Cartr D, Chambers SK. 1992. Neu protein over-expression in benign, borderline and malignant ovarian neoplasms. Gynecol Oncol 44: 245–253.PubMedGoogle Scholar
  99. 99.
    Kern JA, Schwartz DA, Nordberg JE, Weiner DB, Greene MI, Torney L, Robinson RA. 1990. Cancer Res 50: 5184–5191.PubMedGoogle Scholar
  100. 100.
    Weiner DB, Nordberg J, Robinson R, Nowell PC, Gazdar A, Greene MI, Williams WV, Cohen JA, Kern JA. 1990. Expression of the neu gene-encoded protein (pl85neu) in human non-small cell carcinomas of the lung. Cancer Res 50: 421–425.PubMedGoogle Scholar
  101. 101.
    Park J-B, Rhim JS, Park S-C, Kim S-W, Kraus MH. 1989. Amplification, overexpression and rearrangement of the erbB-2 proto-oncogene in primary human stomach carcinomas. Cancer Res 49: 6605–6609.PubMedGoogle Scholar
  102. 102.
    Yonemura Y, Ninomiya I, Yamaguchi A, Fushida S, Kimura H, Ohoyama S, Miyazaki I, Endou Y, Tanaka M, Sasaki T. 1991. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short-term prognosis in gastric cancer. Cancer Res 51: 1034–1038.PubMedGoogle Scholar
  103. 103.
    Jaehne J, Urmacher C, Thaler HJT, Friedlander-Klar H, Cordon-Cardo C, Meyer JH. 1992. Expression of the HER-2/neu oncogene product pl85 in correlation to clinicopathological and prognostic factors of gastric carcinoma. J Cancer Res Clin Oncol 118: 474–479.PubMedGoogle Scholar
  104. 104.
    Jain S, Filipe MI, Gullick J, Linehan J, Morris RW. 1991. c-erbB-2 proto-oncogene expression and its relationship to survival in gastric carcinoma: an immuno histochemical study on archival material. Int J Cancer 48: 668–671.PubMedGoogle Scholar
  105. 105.
    Hilton DA, West KP. 1992. c-erbB-2 oncogene product expression and prognosis in gastric carcinoma. J Clin Pathol 45: 454–456.PubMedGoogle Scholar
  106. 106.
    Tateishi M, Todat, Miniamisono Y, Nagasaki S. 1992. Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. J Surg Oncol 49: 209–212.PubMedGoogle Scholar
  107. 107.
    Bargmann CI. 1988. The neu/c-erbB-2 oncogene. In Reddy EP, Skalka AM, Curran T (eds), The Oncogene Handbook. Elsvier Science Publishers BV: Amsterdam.Google Scholar
  108. 108.
    Weiner DB, Kokai Y, Wada T, Cohen JA, Williams WV, Greene M. 1989. Linkage of tyrosine kinase activity with transforming ability of the pl85neu oncoprotein. Oncogene 4: 1175–1183.PubMedGoogle Scholar
  109. 109.
    Segatto O, Lonardo F, Pierce HH, Bottaro DP, Di Fiore PP. 1990. The role of auto-phosphorylation in modulation of erbB-2 transforming function. New Biol 2: 187–195.PubMedGoogle Scholar
  110. 110.
    Yarden Y. 1990. Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active. Proc Natl Acad Sci USA 87: 2569–2573.PubMedGoogle Scholar
  111. 111.
    Peles E, Ben-Levy R, Or E, Ullrich A, Yarden Y. 1991. Oncogenic forms of the neu/HER-2 tyrosine kinase are permanently coupled to phospholipase Cy. EMBO J 8: 2077–2086.Google Scholar
  112. 112.
    Lonardo F, Di Marco E, King CR, Pierce JH, Segatto O, Aaronson Sa, Di Fiore PP. 1990. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. New Biol 2: 992–1003.PubMedGoogle Scholar
  113. 113.
    Lehvaslaiho H, Lehtola L, Sistonen L, Alitalo K. 1989. A chimeric EGF-R-neu protooncogene allows EGF to regulate neu tyrosine kinase and cell transformation. EMBO J 8: 159–166.PubMedGoogle Scholar
  114. 114.
    Lee J, Dull TJ, Lax I, Schlessinger J, Ullrich A. 1989. HER-2 cytoplasmic domain generates normal mitogenic and transforming signals in a chimeric receptor. EMBO J 8: 167–173.PubMedGoogle Scholar
  115. 115.
    Wildenhain Y, Pawson T, Blackstein ME, Andrulis IL. 1990. P185neu is phosphorylated on tyrosine in human primary breast tumors which overexpress neu/erbB-2. Oncogene 5: 879–883.PubMedGoogle Scholar
  116. 116.
    Koch CA, Anderson D, Moran MF, Ellis C, Pawson T. 1991. SH-2 and SH-3 domains: elements that control interactions of cytoplasmic signaling proteins. Science 252: 668–674.PubMedGoogle Scholar
  117. 117.
    Hazan R, Margolis B, Dombalagian M, Ullrich A, Zilberstein A, Schlessinger J. 1990. Identification of autophosphorylation sites of HER-2/neu. Cell Growth Diff 1: 3–7.PubMedGoogle Scholar
  118. 118.
    Segatto O, Lonardo F, Helin K, Wexler D, Fazioli F, Rhee SG, Di Fiore PP. 1992. erbB-2 autophosphorylation is required for mitogenic action and high-affinity substrate coupling. Oncogene 7: 1339–1346.PubMedGoogle Scholar
  119. 119.
    Di Fiore PP, Segatto O, Lonardo F, Fazioli F, Pierce JH, Aaronson SA. 1990. The carboxy-terminal domains of erbB-2 and epidermal growth factor receptor exert different regulatory effects on intrinsic receptor tyrosine kinase function and transforming activity. Mol Cell Biol 10: 2749–2756.PubMedGoogle Scholar
  120. 120.
    Kumar R, Shepard HM, Mendelsohn J. 1991. Regulation of phosphorylation of the c-erbB-2/HER-2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells. Mol Cell Biol 11: 979–986.PubMedGoogle Scholar
  121. 121.
    Stancovski I, Hurwitz E, Leitner O, Ullrich A, Yarden Y, Sela M. 1991. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ErbB2 receptor on tumor growth. Proc Natl Acad Sci USA 88: 8691–8695.PubMedGoogle Scholar
  122. 122.
    Scott GK, Dodson JM, Montgomery PA, Johnson RM, Sarup JC, Wong WL, Ullrich A, Shepard HM, Benz CC. 1991. pl85HER-2 signal transduction in breast cancer cells. J Biol Chem 266: 14300–14305.PubMedGoogle Scholar
  123. 123.
    Harwerth IM, Wels W, Marte BM, Hynes NE. 1992. Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists. J Biol Chem 267: 15160–15167.PubMedGoogle Scholar
  124. 124.
    Fazioli F, Kim H-U, Rhee SG, Molloy CJ, Segatto O, Di Fiore PP. 1991. The erbB-2 mitogenic signaling pathway: Tyrosine phosphorylation of phospholipase Cγ and GTPase-activating protein does not correlate with erbB-2 mitogenic potency. Mol Cell Biol 11: 2040–2048.PubMedGoogle Scholar
  125. 125.
    Segatto D, Lonardo F, Wexler D, Fazioli F, Pierce JH, Bottaro DP, White MF, Di Fiore PP. 1991. The juxtamembrane regions of the epidermal growth factor receptor and gpl85 erbB-2 determine the specificity of signal transduction. Mol Cell Biol 11: 3191–3202.PubMedGoogle Scholar
  126. 126.
    Peles E, Lamprecht R, Ben-Levy R, Tzahar E, Yarden Y. 1992. Regulated coupling of the neu receptor to phosphatidylinositol 3′-kinase and its release by oncogenic activation. J Biol Chem 267: 12266–12274.PubMedGoogle Scholar
  127. 127.
    Weiner DB, Liu J, Cohen JA, Williams WV, Greene MI. 1989. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature 339: 230–231.PubMedGoogle Scholar
  128. 128.
    Brandt-Rauf PW, Rackovsky S, Pincus MR. 1990. Correlation of the structure of the transmembrane domain of the neu oncogene-encoded pl85 protein with its function. Proc Natl Acad Sci USA 87: 8660–8664.PubMedGoogle Scholar
  129. 129.
    Sternberg MJE, Gullick WJ. 1989. Neu receptor dimerization. Nature 339: 587.PubMedGoogle Scholar
  130. 130.
    Gullick WJ, Bottomley AC, Lofts FJ, Doak DG, Mulvey D, Newman R, Crumpton MJ, Sternberg MJE, Campbell ID. 1992. Three dimensional structure of the transmembrane region of the proto-oncogenic and oncogenic forms of the neu protein. EMBO J 11:43–48.PubMedGoogle Scholar
  131. 131.
    Ben-Levy R, Peles E, Goldman-Michael R, Yarden 1992. In press. An oncogenic point mutation confers high affinity ligand binding to the neu receptor. J Biol Chem 267: 17304–17313.PubMedGoogle Scholar
  132. 132.
    Lemoine NR, Staddon S, Dickson C, Barnes DM, Gullick WJ. 1990. Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer. Oncogene 5: 237–239.PubMedGoogle Scholar
  133. 133.
    Stancovski I, Peles E, Ben-Levy R, Lamprecht R, Kelman Z, Goldman-Michael R, Hurwitz E, Bacus S, Sela M, Yarden Y. In press. Signal transduction by the neu/erbB-2 receptor: A potential target for anti-tumor therapy. J Steroid Biochem Mol Biol.Google Scholar
  134. 134.
    Huang SS, Koh HA, Konish Y, Bullock LD, Huang JS. 1990. Differential processing and turnover of the oncogenically activated neu/erbB2 gene product and its normal cellular counterpart. J Biol Chem 265: 3340–3346.PubMedGoogle Scholar
  135. 135.
    Maier LA, Xu FJ, Hester S, Boyer CM, McKenzie S, Bruskin AM, Agron Y, Bast RJ. 1991. Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2. Cancer Res 51: 5361–5369.PubMedGoogle Scholar
  136. 136.
    Pandiella A, Lehvaslaiho H, Magni M, Alitalo K, Meldolesi J. 1989. Activation of an EGFR/neu chimeric receptor: early intracellular signals and cell proliferation responses. Oncogene 4: 1299–1305.PubMedGoogle Scholar
  137. 137.
    Sistonen L, Holtta E, Lehvaslaiho H, Lehtola L, Alitalo K. 1989. Activation of the neu tyrosine kinase induces the fos/jun transcription factor complex, the glucose transporter and orithine decarboxylase. J Cell Biol 109: 1911–1919.PubMedGoogle Scholar
  138. 138.
    Koskinen PJ, Lehvaslaiho H, MacDonald-Bravo H, Alitalo K, Bravo R. 1990. Similar early genes responses to ligand-activated EGFR and neu tyrosine kinases in NIH-3T3 cells. Oncogene 5: 615–618.PubMedGoogle Scholar
  139. 139.
    Yarden Y, Kelman Z. 1991. Transmembrane signaling receptors for cytokines and growth factors. Curr Op Struct Biol 1: 582–589.Google Scholar
  140. 140.
    Jallal B, Schlessinger J, Ullrich A. 1992. Tyrosine phosphatase inhibition permits analysis of signal transduction complexes in pl85 HER-2/neu-overexpressing human tumor cells. J Biol Chem 267: 4357–4363.PubMedGoogle Scholar
  141. 141.
    Stem DF, Hefferman PA, Weinberg RA. 1986. pl85, a product of the neu protooncogene, is a receptor-like protein associated with tyrosine kinase activity. Mol Cell Biol 6: 1729–1740.Google Scholar
  142. 142.
    Kokai Y, Dobashi K, Weiner DB, Myers JN, Nowell PC, Greene MI. 1988. Phosphorylation process induced by epidermal growth factor alters cellular and oncogenic neu (NGL) gene products. Proc Natl Acad Sci USA 85: 5389–5393.PubMedGoogle Scholar
  143. 143.
    Goldman R, Ben-Levy R, Peles E, Yarden Y. 1990. Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: A mechanism for receptor trans-3regulation. Biochemistry 29: 11024–11028.PubMedGoogle Scholar
  144. 144.
    Wada T, Qian X, Greene MI. 1990. Intermolecular association of the pl85neu protein and EGF receptor modulates EGF receptor function. Cell 61: 1339–1347.PubMedGoogle Scholar
  145. 145.
    Qian X, Decker SJ, Greene MI. 1992. pl85c-neu and epidermal growth factor receptor associate into a structure composed of activated kinases. Proc Natl Acad Sci USA 89: 1330–1334.Google Scholar
  146. 146.
    Kornilova ES, Taverna D, Hoeck W, Hynes NE. 1992. Surface expression of erbB-2 protein is post-transcriptionally regulated in mammary epithelial cells by epidermal growth factor and by culture density. Oncogene 7: 511–519.PubMedGoogle Scholar
  147. 147.
    Connely PA, Stern DF. 1990. The epidermal growth factor receptor and the product of the neu proto-oncogene are members of a receptor tyrosine phosphorylation cascade. Proc Natl Acad Sci USA 87: 6054–6057.Google Scholar
  148. 148.
    Spivak-Kruizman T, Rotin D, Pinchasi D, Ullrich A, Schlessinger J, Lax I. 1992. Heterodimerization of c-erbB-2 with different growth factor receptor mutants elicits stimulatory or inhibitory responses. J Biol Chem 267: 8056–8063.Google Scholar
  149. 149.
    Cao H, Decker S, Stern DF. 1991. TPA inhibits the tyrosine kinase activity of the neu protein in vivo and in vitro. Oncogene 6: 705–711.PubMedGoogle Scholar
  150. 150.
    Yarden Y, Weinberg RA. 1989. Experimental approaches to hypothetical hormones: detection of a candidate ligand of the neu proto-oncogene. Proc Natl Acad Sci USA 86: 3179–3183.PubMedGoogle Scholar
  151. 151.
    Yarden Y, Peles E. 1991. Biochemical analysis of the ligand for the neu oncogenic receptor. Biochemistry 30: 3543–3550.PubMedGoogle Scholar
  152. 152.
    Peles E, Bacus SS, Koski RA, Lu HS, Wen D, Ogden SG, Ben-Levy R, Yarden Y. 1992. Isolation of the Neu/HER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell 69: 205–2f6.PubMedGoogle Scholar
  153. 153.
    Wen D, Peles E, Suggs SV, Cupples R, Lu HS, Bacus SS, Hu S, Koski R, Karkare S, Ben-Levy R, Luo Y, Yarden Y. 1992. Molecular cloning of the Neu differentiation factor: A transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell 69: 559–572.PubMedGoogle Scholar
  154. 154.
    Holmes WE, Sliwkowski MI, Akita RW, Henzel WJ, Lee J, Park JW, Yansura D, Abadi N, Raab H, Lewis GD, Shepard M, Kuang W-J, Wood WI, Goeddel DV, Vandlen RL. 1992. Identification of Heregulin, a specific activator of pl85erbB-2. Science 256: 1205–1210.PubMedGoogle Scholar
  155. 155.
    Lupu R, Colomer R, Zugmaier G, Sarup J, Shepard M, Slamon D, Lippman ME. 1990. Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and pl85erbB2 Science 249: 1552–1555.PubMedGoogle Scholar
  156. 156.
    Bacus SS, Huberman E, Chin D, Kiguchi K, Simpson S, Lippman M, Lupu R. 1992. A ligand for the erbB-2 oncogene produce (gp30) induces differentiation of human breast cancer cells. Cell Growth Diff 3: 401–411.PubMedGoogle Scholar
  157. 157.
    Peles E, Ben-Levy R, Tzahar E, Koski R, Wen D, Yarden Y. Submitted. Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2.Google Scholar
  158. 158.
    Lupu R, Colomer R, Kannan B, Lippman ME. 1992. Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses. Proc Natl Acad Sci USA 89: 2287–2291.PubMedGoogle Scholar
  159. 159.
    Huang SS, Huang JS. 1992. Purification and characterization of the neulerbB2 ligand-growth factor from bovine kidney. J Biol Chem 267: 11508–11512.PubMedGoogle Scholar
  160. 160.
    Dobashi K, Davis JG, Mikami Y, Freeman JK, Hamuro J, Greene MI. 1991. Characterization of a neu/c-erbB-2 protein-specific activating factor. Proc Natl Acad Sci USA 88: 8582–8586.PubMedGoogle Scholar
  161. 161.
    Davis JG, Hamuro J, Shin CY, Samanta A, Greene MI, Dobashi K. 1991. Isolation and characterization of a neu protein-specific activating factor from human ATL-2 cell conditioned medium. Biochem Biophys Res Commun 179: 1536–1542.PubMedGoogle Scholar
  162. 162.
    Tarakhovsky A, Zaichuk T, Prassolov V, Butenko ZA. 1991. A 25 kDa polypeptide is the ligand for P185neu and is secreted by activated macrophages. Oncogene 6: 2187–2196.PubMedGoogle Scholar
  163. 163.
    Drebin JA, Stern DF, Link VC, Weinberg RA, Greene MI. 1984. Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene. Nature 312: 579–588.Google Scholar
  164. 164.
    Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI. 1985. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41: 697–706.PubMedGoogle Scholar
  165. 165.
    Drebin JA, Link VC, Weinberg RA, Greene MI. 1986. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc Natl Acad Sci USA 83: 9129–9133.PubMedGoogle Scholar
  166. 166.
    Drebin JA, Link VC, Greene MI. 1988. Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded pl85 molecule exert synergistic anti-tumor effects in vivo. Oncogene 2: 273–277.PubMedGoogle Scholar
  167. 167.
    Drebin JA, Link VC, Greene MI. 1988. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene 2: 387–394.PubMedGoogle Scholar
  168. 168.
    Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. 1989. pl85HER-2 monoclonal antibody has anti-proliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9: 1165–1172.PubMedGoogle Scholar
  169. 169.
    McKenzie SJ, Marks PJ, Lam T, Morgan J, Panicali DL, Trimpe KL, Carney WP. 1989. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, pl85. Oncogene 4: 543–548.PubMedGoogle Scholar
  170. 170.
    Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A. 1990. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER-2/neu gene product. Cancer Res 50: 1550–1558.PubMedGoogle Scholar
  171. 171.
    Tagliabue E, Centis F, Campiglio M, Mastroianni A, Martignone S, Pellegrini R, Casalini P, Lanzi C, Menard S, Colnaghi MI. 1991. Selection of monoclonal antibodies which induce internalization and phosphorylation of pl85HER-2 and growth inhibition of cells with HER-2/Neu gene amplification. Int J Cancer 47: 933–937.PubMedGoogle Scholar
  172. 172.
    Shepard HM, Lewis GD, Sarup JC, Fendly BM, Maneval D, Mordenti J, Figari I, Kotts CE, Palladino MJ, Ullrich A, et al. 1991. Monoclonal antibody therapy of human cancer: Taking the HER-2 proto-oncogene to the clinic. J Clin Immunol 11: 117–127.PubMedGoogle Scholar
  173. 173.
    Kasprzyk PG, Song SU, Di Fiore PP, King CR. 1992. Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res 52: 2771–2776.PubMedGoogle Scholar
  174. 174.
    van Leeuven F, van de Vijver M, Lomans J, van DL, Jenster G, Akiyama T, Yamamoto T, Nusse R. 1990. Mutation of the human neu protein facilitates down-modulation by monoclonal antibodies. Oncogene 5: 497–503.Google Scholar
  175. 175.
    Bacus SS, Kiguchi K, Chin D, King CR, Huberman E. 1990. Differentiation of cultured human breast cancer cells (AU-565 and MCF-7) associated with loss of cell surface HER-2/neu antigen. Mol Carcinogen 3: 350–362.Google Scholar
  176. 176.
    Bacus SS, Stancovski I, Huberman E, Chin D, Hurwitz E, Mills GB, Ullrich A, Sela M, Yarden Y. 1992. Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. Cancer Res 52: 2580–2589.PubMedGoogle Scholar
  177. 177.
    De Santes K, Slamon D, Anderson SK, Shepard M, Fendly B, Momeval D, Press O. 1992. Radiolabeled antibody targeting of the HER-2/neu oncoprotein. Cancer Res 52: 1916–1923.PubMedGoogle Scholar
  178. 178.
    Pastan I, Fitzgerald D. 1991. Recombinant toxins for cancer treatment. Science 254: 1173–1177.PubMedGoogle Scholar
  179. 179.
    Batra JK, Kasprzyk PG, Bird RE, Pastan I, King RC. 1992. Recombinant anti-erbB-2 immunotoxins containing Pseudomonas exotoxin. Proc Natl Acad Sci USA 89: 5867–5871.PubMedGoogle Scholar
  180. 180.
    Crews JR, Maier LA, Yu YH, Hester S, O’Briant K, Leslie DS, DeSombre K, George SL, Boyer CM, Argon Y, Bast RC Jr. 1992. A combination of two immunotoxins exerts synergistic cytotoxic activity against human breast cancer cell lines. Int J Cancer 51: 772–779.PubMedGoogle Scholar
  181. 181.
    Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. 1986. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321: 522–525.PubMedGoogle Scholar
  182. 182.
    Carter P, Presta L, Gorman CM, Ridgway JBB, Henner D, Wong WLT, Rowland AM, Kotts C, Carver ME, Shepard HM. 1992. Humanization of an anti-pl85HER-2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285–4289.PubMedGoogle Scholar
  183. 183.
    Shalaby MR, Shepard MH, Qresta L, Rodrigues ML, Beverley PCL, Feldmann M, Carter P. 1992. Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER-2 proto-oncogene. J Exp Med 175: 271–225.Google Scholar
  184. 184.
    Nishimura T, Nakamura Y, Tsukamoto H, Takeuchi Y, Tokoda Y, Izasawa M, Yamamoto T, Masuko T, Hashimoto Y, Habu S. 1992. Human c-erbB-2 proto-oncogene product as a target for bispecific antibody directed adoptive tumor immunotherapy. Int J Cancer 50: 800–807.PubMedGoogle Scholar
  185. 185.
    Einat M, Resnitzky D, Kimchi A. 1985. Close link between reduction of c-myc expression by IFN and Go/G1 arrest. Nature 313: 597–600.PubMedGoogle Scholar
  186. 186.
    Marth C, Cronauer MV, Doppler W, Ofner D, Ullrich A, Daxenbichler G. 1992. Effects of interferons on the expression of the proto-oncogene HER-2 in human ovarian carcinoma cells. Int J Cancer 50: 64–68.PubMedGoogle Scholar
  187. 187.
    Fady C, Gardner AM, Gera JF, Lichtenstein A. 1992. Interferon-induced increase in sensitivity of ovarian cancer targets to lysis by lymphokine-activated killer cells: Selective effects on HER-2/neu-overexpressing cells. Cancer Res 52: 764–769.PubMedGoogle Scholar
  188. 188.
    Wood DP Jr, Wartinger DD, Reuter V, Cordon-Cardo C, Fair WR, Chaganti RS. 1991. DNA, RNA and immunohistochemical characterization of the HER-2/neu oncogene in transitional cell carcinoma of the bladder. J Urol 146: 1398–1401.PubMedGoogle Scholar
  189. 189.
    Gardiner RA, Samaratunga ML, Walsh MD, Seymour GJ, Lavin MF. 1992. An immu-nohistological demonstration of c-erbB-2 oncoprotein expression in primary urothelial bladder cancer. Urol Res 20: 117–120.PubMedGoogle Scholar
  190. 190.
    Zhau HE, Zhang X, von Eschenbach AC, Scorsone K, Babaian RJ, Ro JY, Hung MC. 1990. Amplification and expression of the c-erbB-2/neu proto-oncogene in human bladder cancer. Mol Carcinogen 3: 254–257.Google Scholar
  191. 191.
    Moriyama M, Akiyama T, Yamamoto T, Kawamoto T, Kato T, Sato K, Watanuki T, Hikage T, Katsuta N, Mori S. 1991. Expression of c-erbB-2 gene product in urinary bladder cancer. J Urol 145: 423–427.PubMedGoogle Scholar
  192. 192.
    Moriyama M, Morishita Y, Mori S, Akiyama T, Kato T. 1990. Ultrastructural localization of c-erbB-2 gene product in transitional cell carcinoma of the urinary tract. Ultrastruct Pathol 14: 399–405.PubMedGoogle Scholar
  193. 193.
    Coombs LM, Pigott DA, Sweeney E, Proctor AJ, Eydmann ME, Parkinson C, Knowles MA. 1991. Amplification and overexpression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer 63: 601–608.PubMedGoogle Scholar
  194. 194.
    Ware JL, Maygarden SJ, Koontz WW Jr, Strom SC. 1991. Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate. Hum Pathol 22: 254–258.PubMedGoogle Scholar
  195. 195.
    Mellon K, Thompson S, Charlton RG, Marsh C, Robinson M, Lane DP, Harris AL, Home CH, Neal DE. 1992. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urol 147: 496–499.PubMedGoogle Scholar
  196. 196.
    Yin XY, Donovan PM, Whiteside TL, Johnson JT, Day R, Herbermah RB, Locker J. 1991. Gene amplification and gene dosage in cell lines derived from squamous cell carcinomas of the head and neck. Genes Chromosomes Cancer 3: 443–454.PubMedGoogle Scholar
  197. 197.
    Kearsley JH, Leonard JH, Walsh MD, Wright GR. 1991. A comparison of epidermal growth factor receptor (EGFR) and c-erbB-2 oncogene expression in head and neck squamous cell carcinomas. Pathology 23: 189–194.PubMedGoogle Scholar
  198. 198.
    Kernohan NM, Blessing K, King G, Corbett IP, Miller ID. 1991. Expression of c-erbB-2 oncoprotein in salivary gland tumors: an immunohistochemical study. J Pathol 163: 77–80.PubMedGoogle Scholar
  199. 199.
    Kahn HJ, Hanna W, Auger M, Andrulis I. 1992. Expression and amplification of neu oncogene in pleomorphic adenomas of salivary gland. Arch Pathol Lab Med 116: 80–83.PubMedGoogle Scholar
  200. 200.
    Collier JD, Guo K, Mathew J, May FEB, Bennett MK, Corbett IP, Bassen Dine MF, Burt AD. 1992. c-erbB-2 oncogene expression in hepatocellular carcinoma and cholangio-carcinoma. J Hepatol 14: 377–380.PubMedGoogle Scholar
  201. 201.
    Omori K. 1991. DNA content and c-erbB-2 oncoprotein expression in hepatic metastases from colorectal carcinoma in relation to clinicopathologic findings and prognosis. Nippon Geka Gakkai Zasshi 92: 1469–1479.PubMedGoogle Scholar
  202. 202.
    Yamaguchi S, Ohki S, Jo T, Imai S, Matsuo K, Hamahata Y, Fukano M, Tokito S, Hasegawa S, Masui H, et al. 1992. Expression of c-erbB-2 protein and vessel invasion in colorectal cancer. Gan To Kagaku Ryoho 19: 34–39.PubMedGoogle Scholar
  203. 203.
    Tsioulias GJ, Muto T, Morioka Y, Yamamoto T, Mori S. 1990. erbB-2 gene expression in colorectal cancer. Jpn J Exp Med 60: 343–349.PubMedGoogle Scholar
  204. 204.
    Weidner U, Peter S, Strohmeyer T, Hassuatter R, Ackermann R, Sies H. 1990. Inverse relationship of epidermal growth factor receptor and HER-2/neu gene expression in human renal cell carcinoma. Cancer Res 50: 4504–4509.PubMedGoogle Scholar
  205. 205.
    Williams TM, Weiner DB, Greene MI, Maguire HC Jr. 1991. Expression of c-erbB-2 in human pancreatic adenocarcinomas. Pathobiology 59: 46–52.PubMedGoogle Scholar
  206. 206.
    Yamanaka Y. 1992. The immunohistochemical expressions of epidermal growth factor, epidermal growth factor receptors and c-erbB-2 oncoprotein in human pancreatic cancer. Nippon Ika Daigaki Zasshi 59: 51–61.Google Scholar
  207. 207.
    Berchuck A, Rodriguez G, Kinney RB, Soper JT, Dodge RK, Clarke-Pearson DL, Bast RC Jr. 1991. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 164: 15–21.PubMedGoogle Scholar
  208. 208.
    Haugen DR, Akslen LA, Varhaug JE, Lillehaug JR. 1992. Expression of c-erbB-2 protein in papillary thyroid carcinomas. Br J Cancer 65: 832–837.PubMedGoogle Scholar
  209. 209.
    Kashima K, Yokoyama S, Nakayama I, Noguchi S. 1991. Immunohistochemical study on expression of c-myc, p53, c-erbB-2 and epidermal growth factor receptor in human thyroid tumors. Acta Histochem Cytochem 24: 563–570.Google Scholar
  210. 210.
    Sato S, Ito K, Ozawa N, Yajima A, Sasano H. 1991. Expression of c-myc, epidermal growth factor receptor and c-erbB-2 in human endometrial carcinoma and cervical adeno-carcinoma. TGohoku J Exp Med 165: 137–145.Google Scholar
  211. 211.
    Bigsby RM, Li AX, Bomalaski J, Stehman FB, Look KY, Sutton GP. 1992. Immuno-histochemical study of HER-2/neu, epidermal growth factor receptor, and steroid receptor expression in normal and malignant endometrium. Obstet Gynecol 79: 95–100.PubMedGoogle Scholar
  212. 212.
    Berchuck A, Rodriguez G, Kamel A, Soper JT, Clarke-Pearson DL, Bast RC Jr. 1990. Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva and vagina. Obstet Gynecol 76: 381–387.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Ilana Stancovski
  • Michael Sela
  • Yosef Yarden

There are no affiliations available

Personalised recommendations